Clinical Trial Update: Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis [Phase 1]

View source ↗

Summary

Phase 1 safety and tolerability trial of PF-06835375 in seropositive systemic lupus erythematosus and rheumatoid arthritis completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis
• Systemic Lupus Erythematosus

Drugs mentioned

• PF-06835375

Snippet

Sponsor: Pfizer | Conditions: Systemic Lupus Erythematosus, Rheumatoid Arthritis | Phase 1 | Status: COMPLETED | Results posted: 2023-10-30